Breaking Finance News

Gabelli announced Tesaro (NASDAQ:TSRO), boosting its stock price target to $175.00 today

Boasting a price of $137.24, Tesaro (NASDAQ:TSRO) traded 0.87% higher on the day. With the last stock price close down -25.01% from the two hundred day average, compared with the S&P 500 Index which has increased 0.05% over the date range. Tesaro has recorded a 50-day average of $130.46 and a two hundred day average of $149.15. Volume of trade was down over the average, with 800,674 shares of TSRO changing hands under the typical 1,253,190

In a report issued Friday July 07, 2017 Gabelli raised the target price of Tesaro (NASDAQ:TSRO) to $175.00 stating a potential upside of 0.28%.

Performance Chart


With a total market value of $0, Tesaro has with a one year low of $83.26 and a one year high of $192.94 .

A total of 10 equity analysts have released a ratings update on TSRO. Eight equity analysts rating the company a strong buy, four equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $89.00.

Brief Synopsis About Tesaro (NASDAQ:TSRO)

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.